Ventana Medical Systems, a member of the Roche Group, has received US Patent No. 8,329,401, "Enzyme-catalyzed metal deposition for the enhanced detection of analytes of interest." The patent provides methods for detecting an analyte of interest in situ, by immunoassay, or by array-based hybridization by binding an enzyme-labeled conjugate molecule to an analyte of interest in the presence of a redox-inactive reductive species and a soluble metal ion.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Browse our free articlesYou can still register for access to our free content.